Drug Discovery 2017

March 27 - 28, 2017 - London UK

SMi Group


SMi proudly presents its exclusive conference on Drug Discovery, taking place on 27th and 28th March 2017. In recent years, the Pharma/Biotech industry has undergone radical changes which have increased are understanding of drug discovery and development, however there are still many hurdles that the industry face. The gap between a laboratory discovery and an approved drug on the market is a decade-long process of laboratory testing, evaluation in animal models and human clinical trials that can cost hundreds of millions. The conference aims to bridge the gaps in approval for drug discovery and development by discussing the latest scientific breakthroughs, exploring novel technologies and approaches that can be used to overcome drug development challenges. The conference will bring together industry leaders who will highlight future opportunities for novel therapeutic discovery. Some of our featured speakers include Lorenz Mayr, VP and Global Head, AstraZeneca Guido Hanaeur, Scientific Director Translational Medicine, Takeda Ulrich Schopfer, Executive Director, Head Integrated Lead Discovery, Novartis Yolanda Chong, Principal Scientist, Johnson and Johnson Matthias Frech, Director, Molecular Interactions and Biophysics, Merck Serono Wengard Czechtizky, Head of Chemistry, Sanofi Ulrich Schopfer, Executive Director, head Integrated Lead Discovery, Novartis Stephen Pickett, Senior Scientific Investigator, GSK Plus more from AbbVie, UCB Pharma, Eli Lilly, TissUse, Heptares and more. For more information and to register, kindly visit http://www.drug-discovery.co.uk/ddo.

More Information